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In Brief
Damaged mitochondria are thought to
accumulate if mitophagy is impaired and
to cause Parkinson’s disease by
continuously generating high levels of
toxic reactive oxygen species (ROS).
Pryde et al. show instead that proteolytic
quality control ensues in these organelles
to confine and diminish ROS by
degrading the ROS-producing domain of
complex I.
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Mitochondrial dysfunction is implicated in numerous
neurodegenerative disorders and in Parkinson’s dis-
ease (PD) in particular. PINK1 and Parkin gene muta-
tions are causes of autosomal recessive PD, and
these respective proteins function cooperatively to
degrade depolarized mitochondria (mitophagy). It is
widely assumed that impaired mitophagy causes
PD, as toxic reactive oxygen species (ROS)-produc-
ingmitochondria accumulate and progressively drive
neurodegeneration. Instead, we report that a LON-
ClpP proteolytic quality control axis extinguishes
ROS in depolarized mitochondria by degrading the
complex I ROS-generating domain. Complex I defi-
ciency has also been identified in PD brain, and our
study provides a compelling non-genetic mecha-
nistic rationale to explain this observation: intact
complex I depletes if mitochondrial bioenergetic
capacity is robustly attenuated.INTRODUCTION
Parkinson’s disease (PD) is the second most prevalent neurode-
generative disorder (Schapira, 2008). Mitochondrial dysfunction
is implicated in most PD genetic variants and is also reported in
sporadic PD, suggesting mitochondrial homeostasis and PD are
connected (Schapira, 2008). For instance, brains from sporadic
PD patients typically display a selective deficiency in mitochon-
drial complex I activity (via an uncertain mechanism), and they
comprise mitochondrial/cellular oxidative damage (Schapira
et al., 1989; Keeney et al., 2006; Parker et al., 2008). Mutations
in PINK1 (amitochondrial kinase) and Parkin (a cytosolic E3 ubiq-
uitin ligase) are two autosomal recessive causes of PD (Kitada
et al., 1998; Valente et al., 2004). PINK1-Parkin function cooper-
atively to degrade damaged/depolarized mitochondria via auto-
phagy (mitophagy) (Narendra et al., 2010). PINK1 is the damage
sensor; it is imported into the inner mitochondrial membrane
(IMM) of polarized mitochondria and degraded. Mitochondrial
depolarization terminates IMM import (Malhotra et al., 2013),
so PINK1 rapidly accumulates in the outer mitochondrial mem-2522 Cell Reports 17, 2522–2531, December 6, 2016 ª 2016 The Au
This is an open access article under the CC BY license (http://creativebrane (OMM) and phospho-activates Parkin (Kane et al., 2014)
to initiate mitophagy.
Mitochondria also can produce copious amounts of delete-
rious reactive oxygen species (ROS). Respiratory complex I
has long been considered the predominant source, and complex
I abundance parallels mitochondrial ROS-generating capacity
(Lambert et al., 2010; Miwa et al., 2014). Oxygen is reduced to
ROS via a side reaction with the NADH-reduced flavin cofactor
(Pryde and Hirst, 2011). In isolated mitochondria, the rates
of ROS formation accelerate significantly when inhibitors,
mimicking molecular damage, impair respiration (Kushnareva
et al., 2002). It is assumed that high ROS-generating damaged
mitochondria accumulate if mitophagy fails and these organelles
contribute to, or cause, PD via ongoing oxidative damage to
affected neurons. Yet other than inference, the empirical basis
supporting this orthodoxy is lacking. Little is known about the
fate and properties of the organelles normally cleared bymitoph-
agy; their fundamental ROS-generating capacities are not estab-
lished or defined. It is also feasible that mitophagy-independent
PINK1 and Parkin activities cause PD (Chung et al., 2001; Morais
et al., 2014). Elucidating why PINK1-Parkin deficiency causes
PD remains the outstanding question in the field.
Here we report that damaged mitochondria do not perpetually
generate high ROS, as an intra-mitochondrial LON-ClpP proteo-
lytic quality control axis functions to extinguish ROS in these or-
ganelles by degrading the ROS-producing domain of complex I.RESULTS
Mitochondrial Complex I Is Selectively Degraded in
Depolarized Mitochondria
To determine the fate of complex I in damaged organelles, we
induced mitophagy using canonical methodology (Narendra
et al., 2010), and we chemically depolarized mitochondria with
the protonophore CCCP in SH-SY5Y and HeLa cells. Both cell
types express PINK1 but HeLa cells do not express Parkin (Fig-
ures S1A and S1B). Mammalian complex I comprises 44 discrete
subunits (Zhu et al., 2016). The peripheral arm protrudes into the
matrix and catalyzes NADH oxidation, ROS production, and ubi-
quinone reduction. The membrane arm resides in the IMM and
mediates proton translocation. Recently, high-resolution struc-
tures revealed the arrangement of all constituent subunits and
redox/catalytic centers (Figure S1C) (Zhu et al., 2016).thor(s).
commons.org/licenses/by/4.0/).
(legend on next page)
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In both cell types, CCCP progressively diminished both cata-
lytically core and accessory peripheral arm FV1, FV2, FS1, FS2,
and FA9 subunits (core subunits depicted in Figure S1D); all
decreased by35%–40%, 60%–70%, and 80%–95% following
4-, 8-, and 18-hr CCCP, respectively (Figures 1A and 1B). In
contrast, two subunits residing in the membrane arm, FA10
and ND1, were maintained. However FB8 notably depleted,
thus not all membrane arm subunits were preserved. Peripheral
arm depletion exceeded the magnitude of loss ascribable to mi-
tophagy. In SH-SY5Y cells, a cohort of matrix and IMM proteins
(as well as ND1 and FA10) maximally reduced by 20%–30%;
these were largely unaffected in HeLa cells (Figures S1E–S1G).
A notable exceptionwas the complex III subunit UQCRC2, which
decreased by 60%–70% in SH-SY5Y cells only. Figures 1C and
1D show FV2 immunostaining (core subunit), but not HSP60,
greatly diminished in CCCP-treated HeLa cells. Therefore,
enduring depolarizedmitochondria are devoid of the catalytically
active peripheral arm.
Native-PAGE immunoblot analysis revealed that subunit
depletion corresponds to intact complex I degradation (Figures
1E, 1F, and 1M; Figures S1H and S1I), and both flavin and
Q-site activities robustly diminished (Figures 1G–1I). Neither
the amount nor size of complexes III and IV were affected during
depolarization (Figures 1E and 1F; Figures S1H and S1I), and,
after 18 hr, complex II–IV activities decreased by only 25%
(Figure 1I). As expected, diminished complex I robustly impaired
oxygen consumption rates (Figures 1J and 1K).
Degradative subcomplex intermediates were not observed
when immunoblotting for peripheral arm subunits, but a large
complex emerged when probing for FA10 (Figures 1L and 1M)
and the molecular weight shift was commensurate with mem-
brane arm. Subcomplex abundance increased inversely to
declining intact complex I levels (Figures 1L and 1M). De-
synchronized peripheral and membrane arm degradation is
perhaps not surprisingconsideringdistinctivemodules assemble
into the final configuration (Koopman et al., 2010). Finally, we
confirmed that PINK1 is not requisite for CCCP-induced periph-
eral arm turnover (Figures S1J–S1O). Taken together, the periph-
eral arm is selectively vulnerable to proteolysis after depolariza-
tion independently of PINK1/Parkin/bulk mitophagy.
mDJ Dissipation Signals Peripheral Arm Degradation
What drives complex I degradation following mitochondrial de-
polarization? CCCP equilibrates protons across the IMM,
thereby dissipating themembrane potential (mDJ) and pH differ-
ence (mDpH) components of the proton-motive force (Dp), as
well as terminating Dp-driven ATP synthesis and mDJ-drivenFigure 1. Dp Dissipation Triggers Selective Complex I Peripheral Arm
(A and B) SH-SY5Y and HeLa cells after 4-, 8-, and 18-hr CCCP treatment (n = 5
(C and D) HSP60 and NDUFV2 immunostained HeLa cells ± 18-hr CCCP treatm
(E and F) Native-PAGE complex I, III, and IV levels, following 0- to 8-hr CCCP or
(G and H) Native-PAGE in-gel complex I activity in HeLa cells and quantification
band; n = 3).
(I) Activity measurements in mitochondria isolated from HeLa cells ± CCCP (n =
(J and K) Respiration rates in HeLa cells ± 8-hr CCCP or valinomycin pre-treatm
added as indicated (n = 4).
(L and M) Native-PAGE NDUFA9 and NDUFA10 immunoblots. HeLa cells ± 8- an
See also Figure S1.
2524 Cell Reports 17, 2522–2531, December 6, 2016protein import. We used nigericin (Nig; dissipates mDpH, in-
creases mDJ), valinomycin (Val; dissipates mDJ, increases
mDpH), oligomycin (Oligo; inhibits ATP synthase), and cyclohex-
imide (CHX; inhibits cytosolic translation) to dissect how CCCP
signals proteolysis.
CHX did not significantly alter steady-state complex I levels
(Figures 2A and 2B; Figures S3A and S3B), but it greatly dimin-
ished short-lived TIM23 (Figures S3A and S3B). Therefore,
peripheral arm turnover is a stimulated response to depolarization
andnotattributable tohalf-lifekinetics. FiguresS2AandS2Bshow
only CCCP and Val quenched TMRM+ (a mDJ reporter) and
induced peripheral arm loss (Figures 1E, 1F, and 2A–2D).
Blocking respiration with the complex III inhibitor antimycin A
(Anti.A) only depleted complex I (Figures 2C–2G) and in-gel ac-
tivity (Figures 2H and 2I) when combined with Oligo. Anti.A +
Oligo quenched TMRM+ similarly to CCCP (Figure S2B),
whereas Anti.A alone partially lowered TMRM+ (Figure S2B),
i.e., sufficient mDJ is maintained via ATP hydrolysis by ATP syn-
thase to preserve complex I. The complex I Q-site inhibitor rote-
none (Rot) essentially recapitulated the Anti.A effect (Figures 2E
and 2F). However, we noted that the degradation efficacy of
Rot + Oligo was approximately two times weaker compared to
Anti.A + Oligo. To establish if Rot somehow impairs proteolysis,
we included Rot alongside CCCP and found2-fold less periph-
eral arm depletion (Figures 2J and 2K; Figure S3C). Similar re-
sults were observed with an alternative Q-site inhibitor, piericidin
A (Figures 2J and 2K; Figure S3C).
Activating Mitophagy Triggers Mitochondrial Oxidative
Stress and Peripheral Arm Depletion
Next, we sought to determine if activating mitophagy elevates
mitochondrial ROS production and to explore how complex I
degradation affects ROS. Mitochondrial aconitase (mt-aconi-
tase) activity is an established reporter of intra-mitochondrial
ROS (Gardner et al., 1995). Here, aconitase activity reduced by
50%–60%during 15- to 30-min Anti.A ±Oligo treatment (Figures
3A and 3B). Cells express two aconitase isoforms compartmen-
talized in the matrix and cytosol (Gardner et al., 1995). We iso-
latedmitochondria fromcells at±1-hr Anti.A treatment and found
eradicated aconitase activity; thus, 55% of the total rate is attrib-
utable to mt-aconitase. Rot ± Oligo abolished mt-aconitase ac-
tivity after 1-hr treatment, and CCCP progressively inactivated
mt-aconitase albeit at a slower rate (Figure 3A). Including the anti-
oxidant NAC diminishedCCCPdegradative potency, suggesting
ROS contributes to the orchestration of peripheral arm turnover
(Figure 3C). Thereby, conditions that deplete the peripheral arm
robustly augment mitochondrial ROS production.Proteolysis
).
ent (n = 3).
8-hr nigericin (Nig) or valinomycin (Val) (n = 3).
compared to citrate synthase activity ± 18-hr CCCP (*non-complex I reactive
3).
ent. Oligomycin (Oligo), FCCP, and antimycin A + rotenone (Ant.A + Rot) were
d 18-hr CCCP. All data are presented in the figure as mean + SDM.
Figure 2. mDJ Dissipation Is the Peripheral Arm Degradation Trigger
(A and B) Native-PAGE. HeLa cells ± 8-hr cycloheximide (CHX), antimycin A + oligomycin (Anti.A + Oligo), CCCP, or valinomycin (Val) treatment (n = 3).
(C and D) SH-SY5Y (left panel) and HeLa (right panel) cells ± 8-hr Oligo, Anti.A + Oligo, nigericin (Nig), Val, and CCCP (n = 3).
(legend continued on next page)
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If oxidative stress initiates peripheral arm turnover, why does
complex I maintain after 18-hr Anti.A or Rot treatment? We
probed the precise kinetic relationship between Anti.A exposure
and complex I stability. Remarkably, FS1, FV1, FA9, and FV2
levels declined by 20%–50% after 2- to 4-hr Anti.A, but subse-
quently they recovered to basal levels after 8 hr (Figures 3D
and 3E); the recovery was blocked by CHX, and we observed
concurrent upregulation of nuclear-encoded peripheral arm,
but not membrane arm, transcript levels (Figures 3D–3F). The
magnitude of transcript upregulation is consistent with previ-
ously determined mitochondria-nuclear retrograde signaling
(M€unch and Harper, 2016). Figures 2H and 2I confirm that intact
complex I comprising reconstructed peripheral arm is catalyti-
cally active.
Is mitochondrial ROS production affected by complex I degra-
dation? In live cells ROS measurements were limited to Anti.A
treatments using mitoSOX (as equilibration of ROS reporters
requires mDJ). Anti.A concurrently increased NAD(P)H auto-
fluorescence, which decreases the complex I flavin reduction
potential (Pryde and Hirst, 2011) (Figures 3G and 3H), and stim-
ulated ROS formation by 5- to 6-fold (Figures 3I and 3J).
NAD(P)H intensity maintained during Anti.A treatment (Figures
3G and 3H), but ROS production lowered (Figures 3I and 3J) pro-
portionally to peripheral arm depletion (Figures 3D and 3E).
Furthermore, mitochondria fractionated from CCCP-treated
cells generated significantly less NADH-induced ROS (Fig-
ure 3K). Mitochondrial ROS production progressively diminishes
as complex I is degraded.
LON and ClpP Bind and Degrade the Peripheral Arm
Matrix and IMM proteins are degraded by an elaborate network
of proteases (Quiro´s et al., 2015), including m-AAA as well as
stress-activated LON and ClpP. The proteasome (Radke et al.,
2008) and lysosome (Soubannier et al., 2012) also can mediate
degradation.
Proteasomal or lysosomal inhibition did not affect peripheral
arm turnover (Figures 4A–4D). Silencing LON impaired depolari-
zation-induced FS1 (1.73), FV1 (1.93), FA9 (1.43), and FV2
(2.03) degradation, whereas silencing ClpP retarded FV1
(1.73) and FV2 (3.13) turnover (Figures 4E and 4F; Figures
S3F and S3G), suggesting subunit-dependent proteolytic redun-
dancy and exclusivity. Remnant turnover may reflect residual
LON/ClpP activities or less efficient turnover pathways, and
redundancy is a hallmark of the proteolytic network (Quiro´s
et al., 2015). Silencing LON impaired mt-aconitase degradation
in depolarized mitochondria (Figures S3D and S3E).
Do degradative proteases dock to intact complex I as part of
the degradative cascade?We immuno-captured intact complex I
via FB6; Figure 4G confirms co-precipitation with distal FV2 and
FS1 subunits. LON and ClpP significantly enriched with precipi-
tated intact complex I after 4-hr Anti.A treatment (Figure 4G).(E and F) SH-SY5Y cells ± 18-hr Anti.A ± Oligo or rotenone (Rot) ± Oligo (n = 3).
(G) Native-PAGE NDUFA9 or NDUFA10 immunoblots ± 18-hr Anti.A + Oligo, Ant
(H and I) Native-PAGE in-gel complex I activity (n = 3) and citrate synthase activi
(*non-complex I reactivity).
(J and K) SH-SY5Y cells ± 18-hr Rot, piericidin A (Pier.A), CCCP, CCCP + Rot, o
See also Figure S2.
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able peripheral arm subunits (Figure 4H) (ClpP not unsuccess-
fully precipitated). Finally, Figure 2J revealed that rotenone
impaired peripheral arm turnover, and Figure 4G shows rotenone
diminished Anti.A-induced complex I and LON precipitation,
suggesting Q-site-inhibited complex I is more resistant to prote-
olysis and protease binding.
DISCUSSION
Molecular mechanisms of PINK1-Parkin mitophagy have been
studied intensely; however, the cause of PD is not understood.
Here, we show that the widespread assumption that accumu-
lating impaired mitochondria perpetually generate high toxic
ROS levels requires reconsideration; quality control ensues to
extinguish ROS by degrading complex I and, thus, constraining
the putative toxicity phase (cartoon depiction in Figure 4I). Chal-
lenging studies are required to establish if the limited phase of
high ROS is sufficient to cause PD and to determine if acceler-
ating complex I degradation can be harnessed therapeutically.
We also provide evidence for an intriguing stress-induced
complex I degradation-retrograde signaling-protein synthesis/
import-repair cascade. Elucidating the orchestration of retro-
grade signaling and how repair is coordinated require further
investigation, but presumably they enable respiration renewal
by clearing/repairing damage-prone peripheral arm if the organ-
elles retain some mDJ. ATP hydrolysis by ATP synthase gener-
ates mDJ when the respiratory chain is impaired; thus, if
glycolytic capacity is low (e.g., neurons [Almeida et al., 2001]),
the repair pathway will fail, which might explain complex I defi-
ciency in PD brains; thus far only mtDNA mutations had been
considered (Kraytsberg et al., 2006). Intriguingly, in both PD hu-
man brains and PD models, as well as generic ROS-inducing
conditions, peripheral arm subunits are selectively oxidized
(including FS1, FS2, FV1, and FS6) (Keeney et al., 2006; Chinta
et al., 2007; Danielson et al., 2011; Chouchani et al., 2013; Gor-
enkova et al., 2013). The LON-ClpP degradative axis now pro-
vides a plausible mechanistic foundation to bridge deficiency
with oxidative damage.
Comprehensive in vitro experimentation is required to unravel
the degradative mechanism. Elucidating degrons and inter-sub-
unit degradative dependencies for all constituent peripheral arm
subunits is experimentally daunting, considering single-point
mutations can destabilize intact complex I (Varghese et al.,
2015). Robust investigation will require structural determination
of degradative intermediates combined with carefully executed
mutagenesis. Previous studies revealed LON comprises speci-
ficity for both oxidized peptide and Fe-S clusters (Bota and Da-
vies, 2002; Ngo and Davies, 2009; Bender et al., 2011; Kim et al.,
2015). Thereby, complex I Fe-S clusters could form ROS sen-
sors, with their susceptibility to oxidation signaling degradationi.A, CCCP, or Val.
ty (cell lysates) (n = 5). SH-SY5Y cells ± 18-hr CCCP, Anti.A, or Anti.A + Oligo
r CCCP + Pier.A (n = 3). All data are presented in the figure as mean + SDM.
(legend on next page)
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in combination with oxidized polypeptide or hydrophobic
patches in denatured regions (Nishii et al., 2005; Ondrovicova´
et al., 2005).
The finding that Q-site-inhibited complex I is less vulnerable
to turnover provides a mechanistic foundation for subsequent
studies and indicates that theQ-site apparatus systemically con-
trols the propensity of peripheral arm degron formation. Inactive
complex I reverts to a distinctive deactive state (Zhu et al., 2016)
in vitro (Kotlyar and Vinogradov, 1990) and in vivo (Maklashina
et al., 2002). Deactive conformational change is largely restricted
to Q-site architecture, exposing thiols in ND1, ND3, and FA9
(Galkin et al., 2008; Babot et al., 2014) to oxidation/redox modi-
fication (Gorenkova et al., 2013). Rotenone retards the deactive
transition (Grivennikova et al., 1997) by probably binding
peptide, which drives the conversion so complex I is jammed
into a non-deactivate conformation. Accordingly, the deactive
enzyme may form the degradative ground state by revealing de-
grons/exposing oxidizable peptide, which enables subsequent
denaturation and damage contagion in a feedforward-like pro-
teolytic mechanism. Considering rotenone- and MPP- (another
Q-site inhibitor) treatedmice exhibit parkinsonism, a convolution
of defective respiration and suppression of complex I degrada-
tion may contribute.
In conclusion, our study establishes a fundamental connectiv-
ity between mitochondrial homeostasis and complex I. Previ-
ously, complex I deficiency in diseases such as PD has been
considered in the context of genetic defects in constituent sub-
units and assembly factors. We now show complex I stability is
governed by an additional non-genetic regulatory dimension.
We provide a conceptual framework that couples complex I
activity/abundance with perturbed cellular homeostasis. For
instance, disease-associated pathways that trigger systemic
or local depolarization of the mitochondrial pool, such as
augmented nitric oxide during endoplasmic reticulum (ER)
dysfunction or excitotoxicity, should induce peripheral arm
depletion.
EXPERIMENTAL PROCEDURES
Cell Culture
HeLa (S3) and fibroblasts were cultured in DMEM Glutamax (Life Technolo-
gies) and SH-SY5Y cells in DMEM/F12 (Life Technologies) supplemented
with 10% fetal bovine serum (FBS, Life Technologies), 1 mM pyruvate (Life
Technologies), non-essential amino acids (Life Technologies), and penicillin/
streptomycin. Cells were cultured in a 37C, 5% CO2 humidified atmosphere.
SDS-PAGE and Immunoblots
1% Triton X-100 extracts (supplemented with 13 EDTA-free protease/phos-
phatase inhibitors, Pierce) were equally loaded (bicinchoninic acid [BCA] pro-Figure 3. Activating Mitophagy Induces Mitochondrial Oxidative Stres
(A and B) Aconitase activity in HeLa cells after antimycin A (Anti.A) ± oligomycin
cytosolic isoform. (n = 4–5).
(C) HeLa cells ± 8-hr CCCP ± NAC (n = 3).
(D and E) Anti.A-treated SH-SY5Y cells ± cycloheximide (CHX) (n = 3).
(F) mRNA levels in SH-SY5Y cells ± Anti.A treatment (n = 3).
(G and H) NAD(P)H autofluorescence (a.u.) in mitochondrial-GFP (mt-GFP)-expre
(I and J) Rates (a.u.) of ROS in mt-GFP SH-SY5Y cells incubated with mitoSOX a
(K) NADH-induced H2O2 production in mitochondria isolated from HeLa cells ± 8
See also Figure S2.
2528 Cell Reports 17, 2522–2531, December 6, 2016tein assay), DTT reduced, resolved using SDS-PAGE (pre-cast 4%–12% gels;
Novex, Life Technologies), and transferred (wet transfer) onto polyvinylidene
fluoride (PVDF) membranes (GE Healthcare, Amersham Hybond, 0.45 mm).
Membranes were blocked and then incubated with primary antibody overnight
(4C), followed by 1:2,000 horseradish peroxidase (HRP)-conjugated second-
ary antibodies (Dako) for 1 hr. Enhanced chemiluminescence (ECL) Clarity
chemiluminescent substrate (Bio-Rad) was used to detect immunoreactive
proteins by the ChemiDocMP (Bio-Rad) or X-ray film. Unless otherwise stated,
all immunoblots are adjusted for b-actin level and normalized to untreated
samples (100%).
Blue Native-PAGE and in-Gel Complex I Activity Measurements
Cell pellets were solubilized in 50 mL 1 M 6-aminocaproic acid, 50 mM bistris
(pH 7, HCl), and 1.5% n-Dodecyl b-D-Maltopyranoside supplemented with
protease inhibitors. Clarified lysates were added to Serva blue G loading buffer
and loaded onto non-commercial 3%–12% acrylamide gels (Scha¨gger, 1995).
Complexes were sufficiently resolved and membranes subsequently pro-
cessed as standard.
For in-gel activity measurements, the cathode buffer was replaced after
12 min with 50 mM tricine and 15 mM bistris without Serva blue. After
65 min, the gels were stained with a 2 mM Tris (pH 7.4, HCl), 150 mM NADH,
and 3 mM nitroblue tetrazolium for 1–2 hr at 37C. The assay buffer was
exchanged with 10% acetic acid-40% methanol followed by distilled water.
Gels were scanned and intensity quantified using ImageJ software.
Enzyme Kinetics and Respiration Measurements
For citrate synthase activity, the conversion of 5,5’-dithio-bis-[2-nitrobenzoic
acid] (DTNB) to thionitrobenzoic acid (TNB) in clarified cell lysates was moni-
tored at 412 nm. Seahorse Technology was used to measure respiration in
HeLa cells ±8 hr prior to CCCP or valinomycin treatment. For aconitase
activity, NADP+ reduction during the conversion of citrate to a-ketoglutarate
was monitored at 340 nm. Respiratory complexes I, II–III, and IV activities
were determined by measuring rotenone-sensitive NADH:Q1 oxidoreduction
(340 nm), antimycin A-sensitive succinate:cytochrome c oxidoreduction
(550 nm), and reduced cytochrome c oxidation (550 nm), respectively.
Real-Time qPCR of mRNA
RNAwas extracted from antimycin A-treated SH-SY5Y cells using the RNeasy
kit (QIAGEN) and converted to cDNA by the QuantiTect reverse transcription
kit (QIAGEN). The QuantiTect SYBR Green kit (QIAGEN) was used with
QuantiTect Primer Assays (QIAGEN) to determine mRNA levels by real-time
qPCR, and measurements were normalized using the transcript levels for
b-actin. Experiments were carried out in triplicate, and each measurement
also was performed in triplicate. Relative expression was calculated using
the DCT method.
Immunofluorescence
HeLa cells were seeded at 33 105 on 24-mmglass coverslips in six-well plates
and cultured overnight. Following requisite CCCP treatment, cells were fixed in
4% paraformaldehyde, PBS washed, and solubilized in PBS-0.25% Triton
X-100 (20 min, room temperature [RT]). Blocking was performed overnight in
PBS-5% BSA (4C). Anti-HSP60 and anti-NDUFV2 (both 5003 in blocking
buffer) were co-incubated for 90 min (RT), followed by anti-rabbit Alexa Fluor
594- and anti-mouse Alexa Fluor 488-conjugated secondary antibodies (5003
in PBS) for 60 min (RT).s and Triggers Peripheral Arm Degradation
(Oligo), rotenone (Rot) ± Oligo. Red zone indicates activity attributable to the
ssing SH-SY5Y cells during Anti.A treatment (n = 3).
nd treated with Anti.A (n = 3).
-hr CCCP (n = 3). All data in the figure are presented as mean + SDM.
(legend on next page)
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Live-Cell Imaging
SH-SY5Y cells expressing mt-GFP or HeLa cells were seeded onto 22-mm
glass coverslips in six-well plates for 48 hr (1 3 105/well), and then they were
loadedwith 25 nMor 10 nMTMRM+ (ThermoFisher Scientific) (30min inHank’s
balanced salt solution (HBSS), RT). For ROS measurements, 20 mM MitoSOX
(HBSS) was added for 10 min prior to rate measurements. NAD(P)H autofluor-
escence was excited at 351 nm and measured between 375 and 470 nm.
LON and ClpP Silencing
RNAi Max (Thermo Fisher Scientific) and Opti-MEM (Thermo Fisher Scientific)
were used to silence 2 3 105 HeLa cells (according to the manufacturer’s in-
structions) with 5 nM small interfering RNA (siRNA) LON (Thermo Fisher Scien-
tific stealth siRNAs; HSS113887 and HSS113888), 5 nM siRNA ClpP (Thermo
Fisher Scientific stealth siRNAs; HSS112033 and HSS112034), or 5 nM control
siRNA (Thermo Fisher Scientific stealth siRNAs negative control) in six-well
plates for 48 hr prior to treatment.
Complex I-LON and ClpP Co-immunoprecipitation
100 mL (800–1,000 mg) of clarified PBS-1.5% n-Dodecyl b-D-Maltopyrano-
side lysateswere incubated with recombinant protein G agarose (rPG agarose)
(Life Technologies) for 45 min, subsequently sedimented, and supernatants
were added to 30 mL sedimented rPG prior coated with anti-NDUFB6 (2003)
or anti-LON (2003) for 2 hr (4C). Beads were washed three times (PBS,
4C), and antibody-antigen conjugates were eluted in 0.1 M glycine (pH 2.5,
Life Technologies) and neutralized by 1M Tris. DTT-reduced, 70C-heated
samples were resolved by SDS-PAGE and antigens were detected by
immunoblot.
Statistical Analysis
All data are expressed as the mean + SD of the mean (SDM). Statistical
significance was calculated by using Student’s t test, the nonparametric Krus-
kal-Wallis test (comparing more than two datasets), or the nonparametric
Mann-Whitney test (comparing two datasets) on at least triplicate experiments
(see figure legends). Considered significant, p < 0.05 is denoted with a single
asterisk whereas p < 0.01 and p < 0.001 are denoted with two and three aster-
isks, respectively.
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